1. Home
  2. BIRD vs GRML Comparison

BIRD vs GRML Comparison

Compare BIRD & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$2.34

Market Cap

30.1M

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$4.63

Market Cap

29.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BIRD
GRML
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.1M
29.2M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
BIRD
GRML
Price
$2.34
$4.63
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
649.8K
6.2M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
20.22
31.25
EPS
N/A
N/A
Revenue
$152,466,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$35.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.16
52 Week High
$24.31
$11.66

Technical Indicators

Market Signals
Indicator
BIRD
GRML
Relative Strength Index (RSI) 40.84 60.68
Support Level $2.22 $0.20
Resistance Level $2.71 $11.66
Average True Range (ATR) 0.20 0.54
MACD 0.04 0.32
Stochastic Oscillator 13.33 38.62

Price Performance

Historical Comparison
BIRD
GRML

About BIRD Allbirds Inc.

Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: